I own PSTI but rarely post anymore
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Two of my three NoBRAINER's hit 52 week highs in the last two days :) My third pick will probably remain idle until the day it jumps 500% JMHO
I'm thinking of changing my name to Rodney Dangerfield cause I just don't get any respect - lol
Question - If you buy HPGS.OB you are also getting some exposure to BCTE.OB and the opposite is also true so the question is:
Has anyone done a valuation of both companies with an opinion as to which is stock would be undervalued compared to each other and at what ratio would they be considered equally valued?
Thanks in advance.
Meeting with management of Pluristem Therapeutics
Written by Ray Dirks
Friday, 21 January 2011 01:53
I had breakfast with management of Pluristem Therapeutics (NASDAQ: PSTI) yesterday and the discussion turned towards the next indication the Company will focus on using their proprietary PLX cells. PLX cells are placental-derived mesenchymal stromal cells grown via a proprietary three dimensional (3D) technology. Pluristem is actively working on the use of PLX cells for Intermittent Claudication (IC) where a Phase II trial will begin in the spring and Critical Limb Ischemia (CLI) where a Phase II/III trial will begin in the fall.
The Company indicated that their PLX cells are essentially a sophisticated drug delivery vehicle for diseases where there is an “ischemic/inflammatory” element. The Company is considering neuropathic pain as a next indication after PAD because neuropathic pain has a significant “ischemic-inflammatory” element, PLX cells have shown to be extremely effective for neuropathic pain in animal studies, the cells can be easily injected locally for this indication, and the Company can go immediately into Phase II clinical trials.
Neuropathic pain is a chronic condition caused by inflammatory diseases such diabetes, viral infections and chemotherapy. The market for neuropathic pain has been estimated to increase from $6 billion in 2008 to $9.7 billion in 2018 worldwide.
My hypothesis is that Pluristem’s PLX cells may be able to fill the void in the neuropathic pain market created by the failure of anti-nerve growth factors. On December 28, 2010, it was announced that the U.S. Food and Drug Administration (FDA) notified Johnson & Johnson (NYSE:JNJ) that the development program for their drug fulranumab had been put on hold over concerns that this drug and others in the class of compounds categorized as the anti-nerve growth factors (NGF) may be associated with a condition representing either rapidly progressive osteoarthritis or a disease known as osteonecrosis. These conditions may result in the need for total joint replacement. Similar drugs in this class that are under development by AstraZeneca PLC (NYSE:AZN) and Regeneron Pharmaceuticals (NASDAQ: REGN) have also reportedly been put on hold.
Pluristem’s PLX cells treat neuropathic pain via a different mechanism of action than nerve-growth inhibitors, acting by secreting a blend of therapeutic proteins in response to signals sent by inflamed, ischemic tissue. Pluristem, together with its scientific collaborators and experts in the field, have performed preclinical studies in two animal models of inflammatory and neuropathic pain. Inflammation was induced via chemicals in a rat model and PLX cells were injected locally into the inflamed area two days later with pain levels assessed daily. A second model involved a chronic constriction injury (CCI) of the sciatic nerve in the mouse where PLX cells were subsequently injected. The results of these experiments showed that treatment with Pluristem’s PLX cells had a dramatic beneficial effect on pain. In the first model, animals injected with PLX cells achieved a reduction in pain, which was achieved and maintained longer than with standard opiate treatments. In the second model, PLX cells injected at the nerve injury site attenuated both mechanical and thermal sensitivity.
These studies suggest that Pluristem’s proprietary PLX cells can be a viable new therapy for the treatment of neuropathic and inflammatory pain. PLX cells may fill the void in the development of new products for neuropathic pain and ergo, my recommendation.
Disclosure: No Positions
Read the full report: http://biomedreports.com/2011012162667/meeting-with-management-of-pluristem-therapeutics.html?utm_source=twitterfeed&utm_medium=twitter#ixzz1CwMfRbLn
Read the full report: http://biomedreports.com/2011012162667/meeting-with-management-of-pluristem-therapeutics.html?utm_source=twitterfeed&utm_medium=twitter#ixzz1CwKyWTQT
Agencies Agree to Consider Clinical Studies Proposal for Pluristem Pipeline
By Patrick Crutcher
One of the companies whose stock has risen over 150% since we started covering it in early October, Pluristem Therapeutics Inc. (PSTI), today announced that both the European Medical Agencies (EMA) and the Food and Drug Administration (FDA) have come to agreement about Company’s planned clinical development program for PLX-PAD.
Based on the feedback from both the EMA and FDA, Pluristem feels that it is now in a position to advance towards two clinical studies with its PLX-PAD cells: a joint FDA-EMA Phase II/III study of PLX-PAD for CLI and a Phase II study for IC under the FDA and the Paul Ehrlich Institute, the German competent authority in the European Union.
“PLX-PAD has shown promise throughout its initial clinical development, and I am pleased that both the EMA and FDA have acknowledged our proposed comprehensive clinical development plan, which may lead to an advanced cell therapy product that could help millions of PAD patients.
"The completion of two Phase-I CLI clinical studies, performed in parallel in Germany and the U.S., placed Pluristem in a unique position to discuss with the regulatory agencies an approach that should allow a single clinical study protocol to be accepted by both agencies“, commented Zami Aberman, chairman and chief executive officer of Pluristem.
“What is particularly exciting about this development,” continued Aberman, “is that it places us – for the first time – on-track for a potentially preventative treatment for PAD in addition to treating amputation-destined cases."
“PLX-PAD has shown an early read-out of efficacy throughout its clinical development and I am pleased that PLX-PAD has made the necessary progress from a regulatory perspective, to move forward with advanced trials,” commented Edwin Horwitz, MD, PhD, president of the International Society for Cell Therapy, and the head of Pluristem’s scientific advisory board. “I am excited that the PLX-PAD clinical trials will be conducted in the EU and the U.S. under the same clinical protocol, bringing the therapy closer to market and to those CLI patients in need of improved therapies.”
PSTI's cell therapy obtains its cells from the placenta, or after-birth, which comes after the baby’s birth. Accordingly, Pluristem Therapeutics provides the solution to the embryonic stem cell controversy since Pluristem’s cells are not embryonic – in fact, Pluristem does not harm or even touch the donor to obtain its cells. Pluristem Therapeutics gets its cells from what has been designated as medical waste until now.
Pluristem grows its cells in a fashion that is protected by patents. The cells can be given “off-the-shelf” without any matching needed between Pluristem Therapeutics’ cells and the patient receiving the cells. Once injected, Pluristem’s cells, called PLX (Placental eXpanded) cells, respond to signals sent from injured tissue to secrete a mixture of anti-inflammatory and new-blood-vessel forming proteins that treats the injury.
Full Phase 1 data from their trial investigating PLX cells is expected sometime this quarter. In September, they announced results from the 3-month follow up of 21 patients, where PLX-PAD was found to be safe and well-tolerated. This initial data was quite promising: 13/21 patients (62%) had improvements in blood flow and tissue oxygenation, and 17/21 patients (81%) had measured improvements in quality of life (as measured by the King's College Score for Quality of Life assessment). Additionally, 15/21 patients (71%) experienced a reduction in pain from baseline. If their initial results still hold, it would be extremely promising for the future in this indication. Today's regulatory news speaks to the potential their treatment offers CLI patients.
While investors have been excited about Pluristem Therapeutics' progress, we would urge our readers to be aware of a $75 million existing shelf registration, that was made effective on January 11th. In October 2010, Pluristem announced that it had raised approximately $5.25 million through a private placement. That offering included 4,375,000 shares of common stock at a per share purchase price of $1.20 and four year warrants to purchase 2,625,000 shares of common stock at an exercise price of $1.80 per share, exercisable six months following the issuance. Another capital raise sometime in 2011 is certainly something that should be considered going forward; for now, they have enough cash until the end of 2011.
Keep in mind that management at Pluristem is currently seeking licensing agreements for a partnership in several indications, like Crohn’s, MS, Ischemic stroke and others. Following the Mesoblast deal with Cephalon, Pluristem should be able to secure a similar, but smaller deal. Once they have a solid balance sheet, Pluristem can really push their pipeline deeper into trials and initiate studies in different indications like neuropathic pain and stroke. Their pipeline seems ripe for exploration, only question is, which big pharma wants to go along for the ride?
More info:
Pluristem’s $75 million shelf.
Positive 3-month data from Phase 1 study in CLI / neuropathic pain discovery.
PLX cells may help treat ischemic stroke.
Top-line interim results from the Phase 1 study in CLI.
$5 milion capital raise in October.
Disclosure: No position
http://seekingalpha.com/article/247163-agencies-agree-to-consider-clinical-studies-proposal-for-pluristem-pipeline?source=TheMotleyFool
Thanks for including BLTI in your charts. APNT also hit a 52 week high today and is one of my other NOBRAINER picks :)
I have no brains left to offer but I have been averaging up on PSTI and bought more today at $2.87 but I have a few others on my watch list that may be getting ripe even if I can't add any more to the official picks. NNVC might be getting close but if good news does come, it could be a hard one to catch.
oops got dyslexic ticker PSTI
Looks like holding MTREE will pay off nicely if we end up with a profitable company that has over 20 million in revenue. Should be a good year with the elections. Market cap is only about 6.5 million and it tightly held. When is the RS supposed to become effective?
I know most OTC LOI's are not worth the paper they are printed on so I don't expect much stock traction until the deal is complete. But then again most OTC's don't have insiders holding large percentages of common shares and wait 2 years between PR's - lol
Pluristem Announces Closing Of Public Offering Of Common Stock And Warrants To Purchase Common Stock
HAIFA, Israel, Feb. 1, 2011 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced the closing of its previously announced firm commitment underwritten public offering of 11,000,000 units, with each unit consisting of one share of the Company's common stock and one warrant to purchase 0.4 of a share of common stock, at a purchase price of $3.25 per unit.
The underwriters have exercised in full their over-allotment option to purchase an additional 1,650,000 shares of the Company's common stock and additional warrants to purchase up to 660,000 shares of the Company's common stock. The net proceeds to the Company are expected to be approximately $38 million, assuming no exercise of the warrants and after deducting underwriting commissions and discounts and estimated offering expenses payable by the Company.
Oppenheimer & Co. Inc. acted as the sole bookrunner and Needham & Company, LLC acted as co-lead manager for the offering. Maxim Group LLC and National Securities Corp participated in the selling group for the offering. Leader Capital Markets Ltd. advised the Company as did Roth Capital Partners, LLC.
The securities described above were sold by Pluristem pursuant to a "shelf" registration statement on Form S-3 previously filed with the Securities and Exchange Commission (SEC) on December 22, 2010 and declared effective by the SEC on January 11, 2011. A prospectus supplement in connection with the offering, dated January 27, 2011, was filed with the SEC on January 28, 2011 and is available on the SEC's website at http://www.sec.gov . A copy of the prospectus supplement and the accompanying base prospectus may be obtained by sending a request to Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 300 Madison Avenue, 4th Floor, New York, NY, 10017, Telephone number: (212) 667-8563, Email:EquityProspectus@opco.com.
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
I have seen plenty of negative comments allowed as long as they follow the rules and remain civil and focused on the stock. I have been around this stock for a few years myself and personally think that this could finally be the year for progress that will get the stock some positive attention IMHO. Make no mistake there is great risk here so never risk more than you can afford to lose.
Like yourself, I don't have PM. Just look at my profile and latest posts and it will not be hard to figure out what stocks I'm following. The stock you are asking about is one of mine that hit a new 52 week high today.
Anyone here who does not think that PTSI will be at least 3x the current price of $2.85 ($8.55) before the end of this year? I averaged up and bought more today. Follow the Mesoblast story and see what happened shortly after their shelf closed. Compare the market caps, stage of development and potential for success.
Thanks maddogs - you have always been a straight shooter in my book. It looks apparent that LTC technology has fallen behind a new competitor but that does not mean that someone else would not want LTC as it is a very proven tech (in the Ukraine) and competition is inevitable sooner or later. Sad that this has turned into a lotto play and that my concerns that caused me to sell have been proven true. I do hope it works out for those who are holding. I have followed this for so long it is like a book and I still want to see what happens in the final chapter (oops bad choice of words - sorry). At least most of my other favs are doing very well.
Feel free to look at my other posts and see what I mean. Funny thing is one of them I had watched longer than CTUM (ctgi) and even mentioned it on this board about a year ago.
Hit 52 week high - Blue Sky
Hit 52 week high - Blue Sky
Hit 52 week high - Blue Sky
Harris & Harris Group Notes NeoPhotonics IPO
NEW YORK, Feb. 2, 2011 (GLOBE NEWSWIRE) -- Harris & Harris Group, Inc., (Nasdaq:TINY) noted today that NeoPhotonics Corporation has priced its initial public offering (IPO) of 7,500,000 shares of common stock at $11 per share.
Harris & Harris Group first invested in NeoPhotonics in 2003. As of September 30, 2010, the most recent date on which Harris & Harris Group valued its investment in NeoPhotonics, our preferred convertible shares were valued at $6,745,442. Prior to the IPO, Harris & Harris Group's preferred shares of NeoPhotonics converted into approximately 400,900 shares of common stock. Harris & Harris Group purchased an additional 50,000 shares of common stock in the IPO.
NeoPhotonics is a developer and vertically integrated manufacturer of photonic integrated circuit (PIC) based components, modules and subsystems for use in telecommunications networks. The company's products include active semiconductor, passive PLC and MEMS multi-dimensional switching functions in a single product. This integration is enabled by nanomaterials and nanoscale design and fabrication technologies. NeoPhotonics maintains headquarters in San Jose, California and ISO 9001:2000 certified engineering and manufacturing facilities in Silicon Valley and Shenzhen, China.
Harris & Harris Group is a publicly traded venture capital company that invests in nanotechnology and microsystems. Detailed information about Harris & Harris Group and its holdings can be found on its website at www.HHVC.com.
This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2009, as well as subsequent filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including but not limited to the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The reference to the website www.HHVC.com has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release.
CONTACT: DOUGLAS W. JAMISON
TEL. NO. (212) 582-0900
BLTI catching it's second wind.......
No turning back.
Hey surf, what do you think of ALNY today? Are they coming out of the woodshed?
Getting close to the 52 week high:) Looking forward to the big PR when they announce their first profitable year.
Looks like ARWR (.901) may have put in a triple bottom and is finally waking up. Lots of upside potential. I like it when TA turns around in an emerging company with home run potential and after it has been run through the wringer and survived.
Yes that is Dr. Larry Osborne and you can see other sermons and series at www.searchablesermons.com
You can also get the iphone or Android app for "North Coast Church" as well as podcast.
Mesoblast Reports Strong Cash Position
After Angioblast Acquisition
Melbourne, Australia: 31 January 2011:Global regenerative medicine company, Mesoblast Limited (ASX: MSB; OTC ADR: MBLTY), today reported its quarterly cash position for the period ended 31 December 2010, with cash reserves of $140.6 million.
This flows directly from the recently completed acquisition of United States-based Angioblast Systems Inc. On 7 December 2010, Angioblast entered into a strategic alliance with global biopharmaceutical company Cephalon Inc. (Nasdaq: CEPH) to develop and commercialize adult stem cell therapeutics for degenerative conditions of the cardiovascular and central nervous systems, and for bone marrow transplantation in cancer patients. To gain commercial rights to Angioblast's products, Cephalon made an upfront payment to the company of US$100 million.
Mesoblast expects its cash position to be further strengthened following an Extraordinary General Meeting to be held on 9 February 2011 to consider an additional placement of Mesoblast shares to Cephalon.
About Mesoblast Limited
Mesoblast Limited (ASX: MSB; OTC ADR: MBLTY) is a world leader in the development, manufacture, and commercialization of biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights to a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs). More information - www.mesoblast.com
For further information, please contact:
Julie Meldrum
Corporate Communications Director
T: + 61 (0) 3 9639 6036
E: julie.meldrum@mesoblast.com
For more information, please visit http://202.66.146.82/listco/au/mesoblast/halfyr/2011/int2qpress.pdf.
Looks like a rock and hard place right now. Choices seem to be an RS to keep from delisting or no RS and delisting in which case most funds may be required to sell. I like this company and what they are doing but not willing to enter until these issues are resolved and then see where the price is. The convertibles don't help the situation IMHO.
I could be wrong but that is my thinking right now.
Here is a message that every follower of Jesus can take to heart.
Forgiven? The Hidden Dangers of a “Moral” Lifestyle
http://www.searchablesermons.com/VideoFS.asp?SermonID=275
This as been my biggest concern for NNVC as I expressed years ago on this board. I'm glad they understand what they are up against but at the same time I wish he had not stated his strategy so openly.
Anyone attend the PGA event?
I don't like penny promo rags but here is a write-up from last year that does have some interesting points...
http://theotcinvestor.com/applied-nanotech-otc-bb-apnt-makes-the-move-from-research-to-commercialization-853/
Applied Nanotech (OTC-BB: APNT) Makes the Move from Research to Commercialization
By Justin Kuepper · Monday, October 25th, 2010
Applied Nanotech Holdings Inc. (OTC-BB: APNT), a “pure play” nanotechnology company facilitating product development in important high-growth industries of cleantech, healthcare, defense and more, whose technologies are in the same market as companies like Dupont (NYSE: DD) and Yingli Green Energy (NYSE: YGE). Applied Nanotech is entering a period of accelerated growth resulting from the introduction of a number of breakthrough products powered by its technology.
Applied Nanotech Holdings Inc. (OTC-BB: APNT) is focused on solving technical challenges at the molecular level and rapidly transforming nanotechnology innovations into market-leading products covering a wide range of industries. The company’s three-pronged business model is focused on R&D services, IP licensing and subsidiary or joint venture relationships to commercialize products using its technology – a phase it is just now starting to enter.
Nano Inks Reduce Costs, Improve Margins
Applied Nanotech has developed unique metallic inks that can be printed onto circuit boards in order to save money and boost margins for electronics manufacturers. Instead of using molds and etching metals onto circuit boards, the company’s inks can be rapidly and accurately printed using inkjet or aerosol printers onto a variety of different materials, including those that are very fragile.
The program to develop these metallic inks initially stemmed from Ishihara Chemical in Japan for the development of inkjettable copper inks for use in the PCB industry, where it will receive 4% of Ishihara’s revenues from the sale of inks as royalties when it is rolled out. Now, the company is under contract with several other parties to build similar technologies for other applications. For instance, the Department of Energy (DOE) is interested in using aluminum inks for use in making cheaper solar wafers and recently awarded APNT a $1.6 million grant to establish a pilot manufacturing plant for alumimum inks to be used in solar cell production.
Nano Materials Enhance Sporting Good Technology
Applied Nanotech has also developed unique nano materials that will be used in products ranging from tennis rackets to golf clubs. Using carbon nanotube (CNT) technology, the company has created composite material that results in extremely strong tennis rackets and golf clubs that use 20% less material, resulting in a weight reduction. As a result, sporting good product manufacturers can realize lower costs and higher margins on their product lines, while providing products with improved performance characteristics.
Other applications for this technology are apparent in aerospace and any other industry that demands lighter materials which are still extremely robust. For instance, the firm currently has a contract with the U.S. government to develop this material for ballistics applications, while the same technology could also be used to enhance government buildings essentially rendering them bulletproof.
Enormous Markets Could Generate Near-term Revenues
The market for conductive inks and reinforced CNT material is enormous and growing as consumer electronics and materials continue to grow in popularity. Applied Nanotech is poised for rapid revenue growth with several near-term product launches.
The company expects its partnership with Ishihara to begin producing royalty revenues in early 2011, when Ishihara introduces its copper inks. In addition, its sporting goods partner is expected to also introduce products that will generate royalties for APNT in 2011. Meanwhile, the completed technology can then be taken into new billion dollar markets through joint ventures and other partnerships. As a result, this is one stock that growth investors will want to watch closely over the coming months…
CONTACT: 888-288-5215 · Please read our Full Disclaimer pertaining to this article.
After share price triples, Pluristem to raise $40-50m
Jan 27, 2011 (Globes - McClatchy-Tribune Information Services via COMTEX) -- Stem cell therapy developer Pluristem Therapeutics Ltd. (Nasdaq:PSTI; TASE: PLTR; DAX: PJT) is planning a secondary offering of shares and warrants on Wall Street, following a 193 percent rise in its share price in the three weeks since the start of 2011. The offering is based on its draft prospectus filed with the US Securities and Exchange Commission (SEC).
The company did not disclose how much it plans to raise, but sources inform "Globes" that the figure is $40-50 million.
Last week, Pluristem obtained joint US Food and Drug Administration (FDA) and European Medicines Agency (EMEA) approval for two clinical trials for its placenta-derived cell therapy, PLX-PAD, for blocked arteries in the limbs and heart: and a Phase II/III study for critical limb ischemia (CLI) or severe blockage in the arteries; and a Phase II study for ischemia colitis (IC), or inflammation and injury of the large intestine result from inadequate blood supply. The approval of the Phase II/III study for critical limb ischemia means that the company can leapfrog a Phase II clinical trial, and it may be able to market the treatment after just one multi-center trial, assuming it is a success.
Pluristem's share price has been climbing relentlessly in the past few days. Yesterday's announcement, however, sent the share price down 8.1 percent in after-hours trading on Nasdaq, after rising 5.6 percent during the session to $4.20, giving a market cap of $110 million. Investors apparently expect their holdings to be diluted in the offering. The share price rose 1 percent on the TASE this morning, before trading in the share was suspended ahead of the pricing for the offering.
Pluristem's share price has been rising ever since it received a warm recommendation from Ray Dirks. He predicts that the company will achieve a return of 262 percent a year, and he set a target price $17, more than for times the current share price.
To see more of the Globes or to subscribe to the newspaper, go to
http://www.globes-online.com. Copyright (c) 2011, Globes, Tel Aviv, Israel
Distributed by McClatchy-Tribune Information Services. For more information
about the content services offered by McClatchy-Tribune Information Services
(MCT), visit www.mctinfoservices.com.
Gali Weinreb
Copyright (C) 2011, Globes, Tel Aviv, Israel
If you are buying to hold long-term it seems buying under the $3.25 shelf price lets you buy at the "big boy's" price. If you are doing the market cap comparisons to Mesoblast and consider them equal value, then you will need to adjust for the new shares but there is still a very large discrepancy in valuation for PSTI to "catch up" to:) I averaged up yesterday.
The business view of "waste" is changing into "value" IMHO. How will this affect JBII's business model?
I was hoping that someone might actually try the new clubs before pronouncing them dead - lol
Oh well, this is just the first product with their one of their patented nano techs. The military is testing their products too so they already made money licensing the tech to Lenox and if it catches on they will make even more.
Austin, Texas May 3, 2010 -- Applied Nanotech Holdings, Inc. (OTC BB: APNT) announced that it has received a contract in the amount of $168,643 from the US Army Engineer Research and Development Center's Construction Engineering Research Laboratory (ERDC-CERL) Champaign Office for a research effort to develop stronger, stiffer and tighter composite panels with improved ballistic resistance and reduced weight using carbon nanotube reinforcement. This contract is part of the overall goal of ERDC-CERL research in Multifunctional Materials to improve protection of facilities from ballistic and blast threats as well as improve electromagnetic interference (EMI) shielding, seismic resistance and degradation resistance.
This contract is the result of the successful completion of a feasibility study performed earlier under a materials purchase order (see Press Release Dec. 7, 2009). These new composite materials would lead to ballistic resistant panels that would be thinner and lighter, leading to lower material and transportation costs and decreased burden on building framing, while still maintaining , or improving, ballistic protection. Ballistic resistant panels are used in security walls, safe havens, safe rooms, panic rooms, bullet resistant doors, and as a blast protection barrier for both military and civilian applications.
Applied Nanotech has developed CNT reinforced epoxies for carbon fiber reinforced polymers and glass fiber reinforced polymers. These epoxies have a wide range of applications including sporting goods, wind turbine blades, automotive, aerospace, ballistics, and many other applications.
Great call on the PSTI heads up -lol It has doubled since I mentioned it on this board and I am still liking it for more :)
Anyone going to be at the PGA Merchandise Show, being held in Orlando, FL, January 27-29?
I would like to hear anybody's impression of the new Yonex clubs with Nanopreme(TM) shafts.
The claim is: "...improvements of 14 percent, 21 percent, and 24 percent, in flexural strength (bending strength), flexural modulus (stiffness) and impact strength (addressing external shock) respectively compared to conventional carbon materials. This results in products that are lighter, stronger, and more resilient than existing racquets and golf club shafts. In the case of golf clubs, this results in greater distance giving golfers the edge they are constantly seeking."
Of course you still have to hit it straight - lol
Yonex will be showing off APNT technology for the FIRST time at the PGA Merchandise Show, being held in Orlando, FL from January 27-29, 2011. These clubs will be available for sale in February 2011 and Badminton racquets will be introduced in early March 2011. Yonex plans to release additional products using Nanopreme™ in the future.
"Nanopreme scored improvements of 14 percent, 21 percent, and 24 percent, in flexural strength (bending strength), flexural modulus (stiffness) and impact strength (addressing external shock) respectively compared to conventional carbon materials. This results in products that are lighter, stronger, and more resilient than existing racquets and golf club shafts. In the case of golf clubs, this results in greater distance giving golfers the edge they are constantly seeking."
.................................
If I get all 3 of my NoBrainer Picks in the top five do I get another pick :) lol
Amgen to Acquire BioVex
Posted January 25, 2011
* Amgen to Acquire BioVex
* Generex Announces $3.0 Million Investment
* Great Hill Partners Raises $1.1M for Metro Fiber Brasil - cbl
* ArcLight Capital Partners Raises $382.7M - cbl
* Emancipation Capital Owns 6% of SoundBite Communications - cbl
* Q1 Labs Appoints Brian Cohen CFO
NEW YORK -- Harris & Harris Group, Inc. (Nasdaq:TINY) notes that Amgen and BioVex Group, Inc., today announced that the companies have entered into a definitive acquisition agreement under which Amgen has agreed to acquire BioVex Group, a privately held, venture-funded, biotechnology company headquartered in Woburn, Mass. BioVex Group is developing OncoVEX, a novel oncolytic vaccine in Phase 3 clinical development, that may represent a new approach to treating melanoma and head and neck cancer.
Under terms of the agreement, Amgen will pay up to $1 billion: $425 million in cash at closing and up to $575 million in additional payments upon the achievement of certain regulatory and sales milestones. The transaction has been approved by the boards of directors of each company. It is subject to customary closing conditions, including regulatory approvals, and is expected to close in the first quarter of 2011.
Following the completion of the transaction, BioVex Group will become a wholly owned subsidiary of Amgen.
Harris & Harris Group is an investor in privately held BioVex Group. Harris & Harris Group made its initial investment in BioVex Group in September 2007.
Harris & Harris Group is a publicly traded venture capital company that invests in nanotechnology and microsystems. Detailed information about Harris & Harris Group and its holdings can be found on its website at www.HHVC.com.
Well 12.5x the current $3.96 would be $49.50 just to be on par with Mesoblast market cap (if that article is correct). I only have 11,000 shares, I'd better get some more fast - lol
Pluristem's valuation discrepancy hard to ignore given move into Phase II/III
Written by Ray Dirks
Tuesday, 25 January 2011 08:59
On January 3, 2011, when the stock was trading at $1.50, I issued a note reiterating a BUY recommendation on Pluristem Therapeutics, Inc. (NASDAQ:PSTI) pointing out the discrepancy in valuation between PSTI and Mesoblast Limited (MSB.AX). On January 3rd PSTI’s and MSB’s market was approximately $35 million and $745 million respectively, due in part to the announcement of a collaboration between MSB and Cephalon (NASDAQ: CEPH) potentially valued at over $1.9 billion.
Meeting with management of Pluristem Therapeutics
EMA and FDA acknowledge Pluristem's proposed clinical development plan
PLURISTEM THERA
3.96 +0.71 (+21.85%)
PSTI and MSB are both cell therapy companies and are considered comparables. PSTI, an American company with headquarters in Haifa Israel, uses the Human placenta (afterbirth) as a source of their therapeutic cells while MSB, an Australian company, uses bone marrow as their source of cells. Additionally, PSTI grows their cells in-house in a proprietary bioreactor while it is felt that MSB outsources the expansion of their cells where they are grown in Petri dishes or tissue flasks.
At the time of the January 3rd note, PSTI had completed two Phase I/IIa trials in the US and Germany using their PLX-PAD cell product in peripheral artery disease (PAD) while MSB was entering Phase III trials for the use of their cells as an alternative to bone marrow transplantation in hematological malignancies and in Phase II trials for orthopedic and cardiovascular indications.
On January 18, 2011 PSTI announced the successful completion of a parallel scientific advisory process with the European Medical Agencies (EMA) and the U.S. Food and Drug Administration (FDA) regarding the Company’s planned clinical development program for PLX-PAD. Based on the positive feedback from the EMA and FDA, Pluristem is now advancing towards two clinical studies with PLX-PAD: a joint FDA-EMA Phase II/III study for critical limb ischemia (CLI) and a Phase II study for intermittent claudication (IC), both diseases being subsets of PAD.
From my viewpoint, both PSTI and MSB now have products entering Phase III pivotal trials. However, the discrepancy in valuation between the two companies is still quite large. PSTI and MSB currently have market values of approximately $70 million and $900 million respectively. MSB, therefore, is almost 12.5 times larger than PSTI. Although MSB does have the collaboration in place with CEPH, I believe it is just a matter of time before PSTI also has one or more collaborations in place. Therefore, I am recommending investors take advantage of this valuation discrepancy before it ceases to exist.
Read the full report: http://biomedreports.com/2011012562769/pluristems-valuation-discrepancy-hard-to-ignore-given-advance-into-phase-iiiii.html#ixzz1C5aZqni2
I sure do like this PSTI :) One of the shining stars in my portfolio.
"The output is piped into a couple of tankers outside the building."
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=49458722
So you did not see a a couple of tankers outside the building?
"ask JBI to redirect trucks"... That is a sore subject in my book are you sure you want to go there? Didn't they already do that at the AGM to keep the "faithful suckholders" from selling? Park a tanker truck near the P2O processor when they were no where near production just to give the impression that they were close to operational. A real trust builder.